keyword
MENU ▼
Read by QxMD icon Read
search

FDA Deem Regulation

keyword
https://www.readbyqxmd.com/read/28667092/implications-and-challenges-for-implementation-of-the-fda-s-final-deeming-rule-for-waterpipe-tobacco
#1
Erin L Sutfin, Eric K Soule, Karma McKelvey, Desmond Jenson
For the first time, the Food and Drug Administration's (FDAs) Center for Tobacco Products now has regulatory authority over all tobacco products, including waterpipe tobacco. In the rule expanding its authority to cover all tobacco products, the FDA uses largely a one-size-fits-all approach. However, several aspects of waterpipe tobacco smoking make it unique from other tobacco products, which may require more specific, tailored rules. This paper describes the distinct features of waterpipe tobacco products and accessories, and identifies unique challenges to the current regulation posed by this form of tobacco use...
June 30, 2017: Tobacco Control
https://www.readbyqxmd.com/read/28592404/alcohol-flavoured-tobacco-products
#2
Robert K Jackler, Callie K VanWinkle, Isabela M Bumanlag, Divya Ramamurthi
BACKGROUND: In 2009, the Food and Drug Administration (FDA) banned characterising flavours in cigarettes (except for menthol) due to their appeal to teen starter smokers. In August 2016, the agency deemed all tobacco products to be under its authority and a more comprehensive flavour ban is under consideration. OBJECTIVES: To determine the scope and scale of alcohol-flavoured tobacco products among cigars & cigarillos, hookahs and electronic cigarettes (e-cigarettes)...
June 7, 2017: Tobacco Control
https://www.readbyqxmd.com/read/28483810/evidentiary-support-in-public-comments-to-the-fda-s-center-for-tobacco-products
#3
Natalie Hemmerich, Elizabeth G Klein, Micah Berman
Electronic Nicotine Delivery Systems (ENDS) were introduced into the US market in 2007, and until recently these devices were unregulated at the federal level. In 2014, the US Food and Drug Administration (FDA) published a Notice of Proposed Rulemaking asserting its intention to regulate ENDS and requesting public comments on numerous related issues, including potential limits on the sale of flavored ENDS. This article analyzes key comments submitted to the FDA on the issue of flavor regulation in ENDS and examines the weight and credibility of the evidence presented by both supporters and opponents of regulation...
August 2017: Journal of Health Politics, Policy and Law
https://www.readbyqxmd.com/read/28341768/public-reactions-to-e-cigarette-regulations-on-twitter-a-text-mining-analysis
#4
Allison J Lazard, Gary B Wilcox, Hannah M Tuttle, Elizabeth M Glowacki, Jessica Pikowski
BACKGROUND: In May 2016, the Food and Drug Administration (FDA) issued a final rule that deemed e-cigarettes to be within their regulatory authority as a tobacco product. News and opinions about the regulation were shared on social media platforms, such as Twitter, which can play an important role in shaping the public's attitudes. We analysed information shared on Twitter for insights into initial public reactions. METHODS: A text mining approach was used to uncover important topics among reactions to the e-cigarette regulations on Twitter...
March 24, 2017: Tobacco Control
https://www.readbyqxmd.com/read/28266626/anordrin-eliminates-tamoxifen-side-effects-without-changing-its-antitumor-activity
#5
Wenwen Gu, Wenping Xu, Xiaoxi Sun, Bubing Zeng, Shuangjie Wang, Nian Dong, Xu Zhang, Chengshui Chen, Long Yang, Guowu Chen, Aijie Xin, Zhong Ni, Jian Wang, Jun Yang
Tamoxifen is administered for estrogen receptor positive (ER(+)) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER(+) breast cancer than five years of such treatment. Tamoxifen was also approved by the FDA as a chemopreventive agent for those deemed at high risk for the development of breast cancer. The side effects are of substantial concern because of these extended methods of tamoxifen administration...
March 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28206827/validity-of-the-symbol-digit-modalities-test-as-a-cognition-performance-outcome-measure-for-multiple-sclerosis
#6
Ralph Hb Benedict, John DeLuca, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson, Richard Rudick
Cognitive and motor performance measures are commonly employed in multiple sclerosis (MS) research, particularly when the purpose is to determine the efficacy of treatment. The increasing focus of new therapies on slowing progression or reversing neurological disability makes the utilization of sensitive, reproducible, and valid measures essential. Processing speed is a basic elemental cognitive function that likely influences downstream processes such as memory. The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with MS...
April 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28206826/the-nine-hole-peg-test-as-a-manual-dexterity-performance-measure-for-multiple-sclerosis
#7
Peter Feys, Ilse Lamers, Gordon Francis, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn D Hudson, Richard Rudick
Impaired manual dexterity is a frequently reported disability in people with multiple sclerosis (MS) and is increasingly prevalent with worsening disease. While various tests and patient-reported outcome measures are available, the Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The MS Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with MS...
April 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28075420/the-trend-of-voluntary-warnings-in-electronic-nicotine-delivery-system-magazine-advertisements
#8
Ce Shang, Frank J Chaloupka
Some manufacturers of electronic nicotine delivery systems (ENDS) voluntarily carried health warnings in their advertisements. This study examined these voluntary warnings in magazine ads and plotted their trends between 2012 and early 2015. ENDS magazine ads were obtained through Kantar media and warnings were collected from the Chicago Public Library or the Trinkets and Trash surveillance system. The prevalence of voluntary warnings, warnings with the specific capitalized word "WARNING", and MarkTen warnings were examined after being weighted using factors related to exposure between January 2012 and March 2015...
January 10, 2017: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27709305/analysis-of-the-safety-evaluation-for-premarketing-clinical-trials-of-hemodialyzer-and-of-postmarketing-safety-reports-of-hemodialyzer-in-japan-and-the-us-insights-into-the-construction-of-a-sophisticated-premarketing-evaluation
#9
Masami Saito, Kiyotaka Iwasaki
Our aim was to conduct a scoping review of the regulations for hemodialyzers in the safety evaluation in Japan and the United States, and to evaluate the criteria for premarketing clinical trials and postmarketing safety reports to inform the development of a sophisticated premarketing evaluation in Japan. Regulations for approval of hemodialyzers were identified from the databases of the Ministry of Health, Labor and Welfare in Japan and the Federal Drug Agency (FDA) in the United States (US). The criteria for premarket clinical trials and postmarketing safety reports were evaluated for both countries...
March 2017: Journal of Artificial Organs: the Official Journal of the Japanese Society for Artificial Organs
https://www.readbyqxmd.com/read/27192730/deeming-tobacco-products-to-be-subject-to-the-federal-food-drug-and-cosmetic-act-as-amended-by-the-family-smoking-prevention-and-tobacco-control-act-restrictions-on-the-sale-and-distribution-of-tobacco-products-and-required-warning-statements-for-tobacco-products
#10
(no author information available yet)
The Food and Drug Administration (FDA) is issuing this final rule to deem products meeting the statutory definition of "tobacco product,'' except accessories of the newly deemed tobacco products, to be subject to the Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act). The Tobacco Control Act provides FDA authority to regulate cigarettes, cigarette tobacco, roll-your-own tobacco, smokeless tobacco, and any other tobacco products that the Agency by regulation deems to be subject to the law...
May 10, 2016: Federal Register
https://www.readbyqxmd.com/read/26995792/is-the-e-liquid-industry-regulating-itself-a-look-at-e-liquid-internet-vendors-in-the-united-states
#11
Dmitriy Nikitin, David S Timberlake, Rebecca S Williams
INTRODUCTION: The objective of this study was to assess whether the nascent, but rapidly growing e-liquid industry prohibits Internet sales to minors and employs safety measures to prevent accidental poisonings. METHODS: A stratified simple random sample (n = 120) was selected from the target population (N = 1107) of US online vendors of e-liquid in July 2015. The vendors were stratified and subsequently oversampled by trade association membership and vendor popularity...
October 2016: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/26408554/will-chronic-e-cigarette-use-cause-lung-disease
#12
REVIEW
Temperance R Rowell, Robert Tarran
Chronic tobacco smoking is a major cause of preventable morbidity and mortality worldwide. In the lung, tobacco smoking increases the risk of lung cancer, and also causes chronic obstructive pulmonary disease (COPD), which encompasses both emphysema and chronic bronchitis. E-cigarettes (E-Cigs), or electronic nicotine delivery systems, were developed over a decade ago and are designed to deliver nicotine without combusting tobacco. Although tobacco smoking has declined since the 1950s, E-Cig usage has increased, attracting both former tobacco smokers and never smokers...
December 15, 2015: American Journal of Physiology. Lung Cellular and Molecular Physiology
https://www.readbyqxmd.com/read/26394389/regulation-of-peripheral-nerve-stimulation-technology
#13
REVIEW
Daniel M Birk, Dali Yin, Konstantin V Slavin
The number of peripheral nerve stimulation (PNS) indications, targets, and devices is expanding, yet the development of the technology has been slow because many devices used for PNS do not have formal regulatory approval. Manufacturers have not sought Food and Drug Administration (FDA) approval for PNS devices because of a perceived lack of interest amongst practitioners and patients. Without FDA approval, companies cannot invest in marketing to educate the implanters and the patients about the benefits of PNS in the treatment of chronic pain...
2015: Progress in Neurological Surgery
https://www.readbyqxmd.com/read/26237983/the-legal-and-regulatory-status-of-biosimilars-how-product-naming-and-state-substitution-laws-may-impact-the-united-states-healthcare-system
#14
Jordan Paradise
Alongside the constitutional controversy ultimately addressed by the Supreme Court, the colossal Patient Protection and Affordable Care Act (ACA) ushered in a new paradigm for regulation of biologics by the Food and Drug Administration (FDA). Nestled within the expansive ACA, the Biologics Price Competition and Innovation Act (BPCIA) set forth an abbreviated pathway to market for "biosimilar" and "interchangeable" biological products. While the current BPCIA implementation debate focuses chiefly on the scope of scientific and technical assessments by the FDA and the effect on the emergent biosimilar industry, two issues will prove essential for determinations of access to and costs of the resulting products: how the biosimilar and interchangeable biosimilar biologics are to be named, and whether pharmacist substitution is appropriate for products the FDA deems interchangeable...
2015: American Journal of Law & Medicine
https://www.readbyqxmd.com/read/25317866/the-fda-e-cigarettes-and-the-demise-of-combusted-tobacco
#15
Nathan K Cobb, David B Abrams
In April 2014, nearly 8 years after e-cigarettes were introduced into the U.S. market, the Food and Drug Administration (FDA) made a long-awaited announcement regarding its intention to regulate the devices, deeming them to be subject to regulation as tobacco products. The term "e-cigarette" (which..
October 16, 2014: New England Journal of Medicine
https://www.readbyqxmd.com/read/24340824/no-sisyphean-task-how-the-fda-can-regulate-electronic-cigarettes
#16
Jordan Paradise
The adverse effects of smoking have fostered a natural market for smoking cessation and smoking reduction products. Smokers attempting to quit or reduce consumption have tried everything: "low" or "light" cigarettes; nicotine-infused chewing gum, lozenges, and lollipops; dermal patches; and even hypnosis. The latest craze in the quest to find a safer source of nicotine is the electronic cigarette. Electronic cigarettes (e-cigarettes) have swept the market, reaching a rapidly expanding international consumer base...
2013: Yale Journal of Health Policy, Law, and Ethics
https://www.readbyqxmd.com/read/24166236/development-times-clinical-testing-postmarket-follow-up-and-safety-risks-for-the-new-drugs-approved-by-the-us-food-and-drug-administration-the-class-of-2008
#17
Thomas J Moore, Curt D Furberg
IMPORTANCE: The US Food and Drug Administration (FDA) has advanced multiple proposals to promote biomedical innovation by making new drugs available more quickly but with shorter, smaller, and more selective clinical trials and less rigorous end points. OBJECTIVE: To inform the debate about appropriate standards, we studied the development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the FDA in 2008, when most provisions of current law, regulation, and policies were in effect...
January 2014: JAMA Internal Medicine
https://www.readbyqxmd.com/read/23181572/from-bortezomib-to-other-inhibitors-of-the-proteasome-and-beyond
#18
REVIEW
Daniela Buac, Min Shen, Sara Schmitt, Fathima Rani Kona, Rahul Deshmukh, Zhen Zhang, Christine Neslund-Dudas, Bharati Mitra, Q Ping Dou
The cancer drug discovery field has placed much emphasis on the identification of novel and cancer-specific molecular targets. A rich source of such targets for the design of novel anti-tumor agents is the ubiqutin-proteasome system (UP-S), a tightly regulated, highly specific pathway responsible for the vast majority of protein turnover within the cell. Because of its critical role in almost all cell processes that ensure normal cellular function, its inhibition at one point in time was deemed non-specific and therefore not worth further investigation as a molecular drug target...
2013: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/22233294/pharmaceutical-industry-perspective-on-risk-evaluation-and-mitigation-strategies-manufacturer-take-heed
#19
REVIEW
Susan Nicholson, Janet Peterson, Behin Yektashenas
INTRODUCTION: Enactment of the Food and Drug Administration Amendments Act of 2007 (FDAAA) authorized the FDA to require manufacturers to submit Risk Evaluation and Mitigation Strategy (REMS) when it was deemed necessary to ensure that a drug's benefit outweigh its risk. REMS apply to new drug applications (NDAs), abbreviated new drug applications (ANDAs) and biologics license applications (BLAs). The objective of this review is to describe the impact of REMS requirements on the pharmaceutical industry...
March 2012: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/21321283/medical-device-recalls-and-the-fda-approval-process
#20
Diana M Zuckerman, Paul Brown, Steven E Nissen
BACKGROUND: Unlike prescription drugs, medical devices are reviewed by the US Food and Drug Administration (FDA) using 2 alternative regulatory standards: (1) premarket approval (PMA), which requires clinical testing and inspections; or (2) the 510(k) process, which requires that the device be similar to a device already marketed (predicate device). The second standard is intended for devices that the FDA deems to involve low or moderate risk. METHODS: We analyzed the FDA's high-risk List of Device Recalls from 2005 through 2009...
June 13, 2011: Archives of Internal Medicine
keyword
keyword
114372
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"